Learning Objectives:

  1. Understand the mechanisms by which advanced prostate and other immune-refractory cancers evade anti-tumor immunity
  2. Elucidate therapeutic strategies to enhance innate immunity within the tumor microenvironment, thereby overcoming resistance to immunotherapy.
  3. Discuss the development of immuno-oncology combination clinical trials in molecularly-defined subsets of advanced prostate and endometrial cancers.
Session date: 
08/26/2019 - 12:00pm to 1:00pm CDT
900 East 57th Street
KCBD Auditorium 1103
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Akash Patnaik, MD, PhD, MMSc